Related Experiment Videos
[Active immunization against hepatitis B]
Deutsche Medizinische Wochenschrift (1946)
|February 17, 1984
Summary
The Hevac B Pasteur hepatitis B vaccine is safe and effective, with 93.1% of recipients developing protective antibodies within six months. Antibody response varied by sex and age, with females and younger individuals showing higher initial rates.
Area of Science:
- Immunology
- Vaccinology
- Hepatology
Context:
- Hepatitis B virus (HBV) infection remains a significant global health concern.
- Effective vaccination strategies are crucial for preventing HBV transmission and chronic infection.
- The Hevac B Pasteur vaccine is a key tool in hepatitis B prevention efforts.
Purpose:
- To evaluate the immunogenicity and safety of the Hevac B Pasteur hepatitis B vaccine.
- To assess seroconversion rates and antibody titers following vaccination.
- To identify demographic factors influencing vaccine response.
Summary:
- A 6-month study assessed the Hevac B Pasteur vaccine in 277 individuals, administered in three monthly 5-microgram doses.
- Radioimmunological determination of hepatitis B serologic markers showed 85.7% seroconversion within two months and 93.1% after six months.
- Higher anti-HBs levels were initially observed in females but normalized by six months; age significantly impacted seroconversion rates and antibody concentrations.
Impact:
- The Hevac B Pasteur vaccine demonstrates robust immunogenicity and a favorable safety profile.
- Findings highlight the vaccine's efficacy in inducing protective antibodies against hepatitis B.
- Understanding demographic influences on vaccine response can inform targeted vaccination strategies.